High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma

Abstract

REFERENCES1 Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984-2992. 2 Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot P et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of Quizartinib (AC220) in patientsZ60 years of age with FLT3 ITD positive or negative relapsed/refractory. AML Blood (ASH Ann Meeting Abstr) 2012; 120: Abstract 48. 3 Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.

Targetable genetic features of primary testicular and primary central nervous system lymphomas

“…25 Somatic mutations of MYD88 and CD79B of variable frequency have also been reported. 29,30 Herein, we comprehensively characterize the genetic features of PCNSL and PTL and compare these tumors with systemic DLBCLs of known transcriptional subtypes and PMBL. The goal was to identify targetable lesions, bases of immune privilege in PCNSL and PTL, and unique combinations of genetic alterations in discrete LBCL subtypes.…”

MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma

“…2,4,42 The lack of specificity of the MYD88 L265P mutation for lymphoplasmacytic lymphoma is clearly evident from its presence in up to 30% of activated B-cell type diffuse large B-cell lymphoma and in an even higher proportion of primary cutaneous diffuse large B-cell lymphoma, leg type. [43][44][45][46][47] Additional studies of extranodal marginal zone lymphomas with plasmacytic differentiation may be helpful to determine the utility of MYD88 mutation analysis in extranodal, extramedullary biopsy specimens.…”

Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond

“…exclusive to) a particular entity and can also be found in other lymphomas, though generally at lower frequencies (Table 1). For instance, the MYD88 L265P mutation is detected in a significant fraction of DLBCL of the activated B-cell-like subtype (ABC DLBCL), 5 as well as in primary cutaneous, 45 the central nervous system 46 and testicular large B-cell lymphomas, 47 but also in a minority of patients with CLL 4,[48][49][50] and SMZL. 16,51 As another example, STAT3 mutations have been reported, albeit rarely, in immune, mainly hypoplastic, bone marrow failure characterizing a subset of patients with severe aplastic anemia or myelodysplastic syndrome.…”